Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF.

N Engl J Med. 2004 Aug 19;351(8):781-91.

2.

Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial.

Consoli F, Grisanti S, Amoroso V, Almici C, Verardi R, Marini M, Simoncini E.

Tumori. 2011 Nov-Dec;97(6):737-42. doi: 10.1700/1018.11090.

3.

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.

J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923. Erratum in: J Clin Oncol. 2009 Apr 10;27(11):1923.

PMID:
18591556
4.

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.

Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24.

5.

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW.

J Clin Oncol. 2005 Mar 1;23(7):1420-30. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808.

PMID:
15735118
6.

Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.

Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A, Trudeau ME.

Breast Cancer Res Treat. 2006 Sep;99(1):63-9. Epub 2006 Mar 16.

PMID:
16541316
7.

Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.

Jimeno A, Amador ML, González-Cortijo L, Tornamira MV, Ropero S, Valentín V, Hornedo J, Cortés-Funes H, Colomer R.

Cancer. 2004 May 1;100(9):1833-42.

8.

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.

J Clin Oncol. 2009 Jul 10;27(20):3303-11. doi: 10.1200/JCO.2008.19.4423. Epub 2009 May 18.

PMID:
19451443
9.

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.

Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F.

Breast Cancer Res Treat. 2010 Jul;122(1):211-7. doi: 10.1007/s10549-009-0668-7. Epub 2009 Dec 6.

PMID:
19967556
10.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
13.

Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.

Cancer. 2008 Nov 1;113(9):2422-30. doi: 10.1002/cncr.23852.

14.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Cristofanilli M.

Semin Oncol. 2006 Jun;33(3 Suppl 9):S9-14. Review.

PMID:
16797376
15.

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.

Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, Suzuki E.

Breast Cancer. 2010 Jul;17(3):199-204. doi: 10.1007/s12282-009-0139-3. Epub 2009 Aug 1.

PMID:
19649686
16.

Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V.

Clin Breast Cancer. 2007 Feb;7(6):471-9.

PMID:
17386124
17.

Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.

Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A, Marty M.

Clin Cancer Res. 2008 Nov 1;14(21):7004-10. doi: 10.1158/1078-0432.CCR-08-0030.

18.

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.

Bewick M, Chadderton T, Conlon M, Lafrenie R, Morris D, Stewart D, Glück S.

Bone Marrow Transplant. 1999 Aug;24(4):377-84.

19.

Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.

Park IH, Ro J, Lee KS, Kim EA, Kwon Y, Nam BH, Jung SY, Lee S, Kim SW, Kang HS.

J Clin Oncol. 2010 Jun 1;28(16):2705-11. doi: 10.1200/JCO.2009.26.5884. Epub 2010 Apr 26.

PMID:
20421538
20.

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G.

J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8.

PMID:
8931609

Supplemental Content

Support Center